Posted on 17/03/2010 in Pharmaceutical Company Product News Pfizer has published clinical data from a new trial of its heart disease drug Lipitor, which it believes demonstrates its efficacy among certain high-risk patient groups.
The drug was evaluated in the recent Treating to New Targets trial for its ability to prevent cardiovascular events among sufferers of coronary heart disease and chronic kidney disease when used in an intensive regimen.
It was found that those trialled on an 80 mg dosage of the drug experienced a significantly reduced risk of suffering a major event than those using the 10 mg dosage.
Dr Prakash Deedwania, professor of medicine at the UCSF School of Medicine in San Francisco, suggested this may be significant for those affected by metabolic syndrome or obesity.
He said: "The new data demonstrates that Lipitor 80 mg may help prevent cardiovascular events in these high-risk patients."
Earlier this month, results from a clinical trial of Pfizer's pregabalin pain relief drug were published, showing its efficacy in treating neuropathic pain resulting from traumatic injury.Other news stories from 17/03/2010
Read more in the Zenopa News Archive
How this news is generated
|
